Vitamin D Synthesis and Cutaneous Metabolism
Introduction
The skin is a unique endocrine organ capable of synthesizing vitamin D, a hormone essential for calcium homeostasis, bone health, and numerous extra-skeletal functions. This photosynthetic pathway links UV exposure to systemic health, making the skin's relationship with sunlight both protective (vitamin D) and harmful (photocarcinogenesis).
Understanding vitamin D metabolism is clinically relevant for balancing sun protection recommendations with the need for adequate vitamin D status.
Vitamin D Synthesis Pathway
Overview of Cutaneous Synthesis
Loading diagram...
Step-by-Step Production
| Step | Location | Enzyme/Process | Product |
|---|
| 1 | Epidermis (stratum basale/spinosum) | UVB photolysis | Pre-vitamin D₃ |
| 2 | Skin | Thermal isomerization | Vitamin D₃ |
| 3 | Liver | CYP2R1 (25-hydroxylase) | 25(OH)D (calcidiol) |
| 4 | Kidney | CYP27B1 (1α-hydroxylase) | 1,25(OH)₂D (calcitriol) |
Key Metabolites
| Metabolite | Half-life | Measurement | Normal Range |
|---|
| Vitamin D₃ | 24 hours | Not measured clinically | — |
| 25(OH)D | 2-3 weeks | Standard clinical test | 30-100 ng/mL |
| 1,25(OH)₂D | 4-6 hours | Specialized test | 25-65 pg/mL |
Factors Affecting Cutaneous Synthesis
UV-Related Factors
Loading diagram...
Effect of Skin Pigmentation
Melanin acts as a natural sunscreen, reducing vitamin D synthesis:
| Fitzpatrick Type | Relative Synthesis | MED for Equivalent D₃ |
|---|
| I (very fair) | Highest (reference) | 6-10 min |
| II (fair) | 85-90% | 10-15 min |
| III (medium) | 50-75% | 15-20 min |
| IV (olive) | 30-50% | 25-40 min |
| V (brown) | 15-30% | 40-60 min |
| VI (dark) | 10-20% | 60-90+ min |
Latitude and Seasonal Variation
Loading diagram...
Vitamin D Functions
Classical (Endocrine) Functions
Loading diagram...
Extra-Skeletal Functions
| System | Vitamin D Effect | Clinical Relevance |
|---|
| Immune | ↑ Cathelicidin (LL-37), macrophage function | Infection defense |
| Skin | Keratinocyte differentiation, barrier function | Psoriasis, AD |
| Cardiovascular | Endothelial function, BP regulation | Under investigation |
| Cancer | Antiproliferative, pro-differentiation | Epidemiological associations |
| Muscle | Muscle function, fall prevention | Elderly health |
| Mood | Serotonin synthesis | Seasonal affective disorder |
Clinical Assessment
Vitamin D Status Categories
| 25(OH)D Level | Status | Clinical Implications |
|---|
| <10 ng/mL | Severe deficiency | Rickets, osteomalacia |
| 10-20 ng/mL | Deficiency | Increased fracture risk |
| 20-30 ng/mL | Insufficiency | Suboptimal bone health |
| 30-50 ng/mL | Sufficiency | Optimal for most |
| 50-100 ng/mL | Adequate | No additional benefit proven |
| >100 ng/mL | Excess | Hypercalcemia risk |
Populations at Risk for Deficiency
Loading diagram...
Vitamin D in Skin Disease
Psoriasis
Vitamin D and its analogs are foundational psoriasis treatments:
| Agent | Mechanism | Use |
|---|
| Calcipotriol | VDR activation → ↓ proliferation, ↑ differentiation | Topical (plaque psoriasis) |
| Calcitriol | Same | Topical (limited use) |
| Tacalcitol | Same | Topical (some countries) |
| Combination (calcipotriol + betamethasone) | Synergistic | First-line topical |
Atopic Dermatitis
Lower vitamin D levels are associated with AD severity:
- Vitamin D enhances LL-37 (antimicrobial peptide)
- May reduce S. aureus colonization
- Supplementation studies: mixed results
Other Dermatological Associations
| Condition | Association | Evidence |
|---|
| Vitiligo | Low 25(OH)D in patients | Observational; supplementation trials ongoing |
| Alopecia areata | Low 25(OH)D associated | Observational |
| Melasma | Low 25(OH)D in some studies | Unclear mechanism |
| Skin cancer | Paradox: UV causes cancer but makes D | Complex relationship |
Sunscreen Paradox
Balancing Sun Protection and Vitamin D
Loading diagram...
Position Statements
| Organization | Position |
|---|
| AAD | No safe level of UV for vitamin D; supplement if deficient |
| Endocrine Society | Check 25(OH)D; supplement to >30 ng/mL |
| WHO | Brief unprotected exposure acceptable; avoid burning |
Practical Recommendations
| Population | Recommendation |
|---|
| General healthy adults | Brief sun exposure (5-30 min) + dietary sources |
| High-risk for deficiency | Check 25(OH)D; supplement (600-4000 IU/day) |
| Institutionalized elderly | Supplement 800-1000 IU/day |
| Dark-skinned individuals at high latitudes | Consider routine supplementation |
Vitamin D Supplementation
Dosing Guidelines
| Situation | Daily Dose | Notes |
|---|
| Maintenance (adults) | 600-800 IU | Current RDA |
| Deficiency treatment | 1000-4000 IU | Until replete |
| Severe deficiency | 50,000 IU weekly × 8-12 weeks | Then maintenance |
| Malabsorption | Higher doses; D2 may be preferred | Individualize |
D₂ vs. D₃
| Form | Source | Efficacy |
|---|
| Vitamin D₂ (ergocalciferol) | Plant-derived | Less effective at raising 25(OH)D |
| Vitamin D₃ (cholecalciferol) | Animal-derived, sun | Preferred for supplementation |
Summary
Loading diagram...
Key Clinical Pearls
| Topic | Pearl |
|---|
| UVB only | Only 290-315 nm synthesizes vitamin D; UVA does not |
| Melanin effect | Darker skin needs 5-10× more sun exposure |
| Sunscreen effect | SPF 30 blocks >95% of vitamin D synthesis |
| 25(OH)D | The clinical test; reflects stores over 2-3 weeks |
| Psoriasis | Vitamin D analogs are first-line topical therapy |
| Supplementation | D₃ preferred over D₂; 600-4000 IU/day typical |
| Toxicity | Rare from sun (self-limiting); possible from supplements |